By Sarina Isaacs
Shares of Krystal Biotech slid after the company's first-quarter earnings missed Wall Street expectations.
The stock was down 14% at $139.03, putting shares 11% in the red for the year.
The Pittsburgh company on Tuesday reported a first-quarter profit of $35.7 million, or $1.20 a share, up from $932,000, or 3 cents a share, in the same quarter a year earlier. That fell short of the analyst consensus for $1.43 a share, according to FactSet.
Revenue nearly doubled to $88.2 million from the prior year's $45.3 million, but that also missed analyst estimates of $96.2 million.
The company said it ended the quarter with $765.3 million in cash and investments.
Krystal's signature product is Vyjuvek, a topical gene-therapy treatment used to treat wounds arising from genetic skin condition dystrophic epidermolysis bullosa.
Write to Sarina Isaacs at sarina.isaacs@wsj.com
(END) Dow Jones Newswires
May 06, 2025 12:05 ET (16:05 GMT)
Copyright (c) 2025 Dow Jones & Company, Inc.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.